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Abstrak 
 
Latar Belakang: Darah tali pusat (UCB) merupakan sumber alternatif kepada sel 
tunjang alogenik hematopoetik bagi tujuan pemindahan. Kualiti darah tali pusat yang 
dikumpulkan bergantung pada kandungan hematopoetiknya yang secara langsung 
mempengaruhi hasil ‘engraftment’ dan terapeutik. Demi memastikan kualiti darah tali 
pusat yang dikumpulkan terjamin, kriteria penerimaan darah tali pusat telah diwujudkan 
di bank tali pusat, Pusat Darah Negara (PDN) yang bersandarkan piawaian 
antarabangsa. Namun  ia telah  menyebabkan kadar penyingkiran unit darah tali pusat 
yang dikumpulkan agak tinggi. Kajian ini bertujuan untuk mengenalpasti hubungkait 
antara faktor penderma iaitu ibu dan bayi yang boleh mempengaruhi kualiti kandungan 
hematopoetik darah tali pusat untuk membantu dalam pemilihan penderma dan 
seterusnya mengurangkan pembaziran.  
 
Kaedah/Model: Kajian ini merupakan tinjauan semula kajian keratan rentas yang 
dijalankan dengan meneliti 339 rekod pendermaan darah tali pusat yang berjaya 
dikrioawetkan dalam tahun 2014 di PDN, Malaysia. Maklumat kandungan 
hematopoetik yang dianalisa terhadap darah tali pusat yang dikumpulkan  ialah jumlah 
isipadu darah tali pusat, bilangan sel bernukleus (TNC), kepekatan sel CD34+ dan unit 
pembentuk koloni (CFU). Faktor ibu yang dianalisa ialah umur, kaum, jumlah 
kandungan, tempoh kehamilan, dan kumpulan darah manakala ciri-ciri bayi yang 
dianalisa termasuklah jantina, berat lahir bayi dan kumpulan darah. ANOVA sehala, 
ujian-t tak bersandar, korelasi Pearson dan regresi linear tunggal digunakan untuk 
xiii 
 
menentukan perkaitan antara faktor-faktor tersebut dengan kandungan hematopoetik 
darah tali pusat yang dikumpulkan. 
 
Keputusan: Berdasarkan laporan PDN, hanya 38.85% (692) dari jumlah darah tali 
pusat yang dikumpulkan (1781) pada tahun 2014 memenuhi syarat penerimaan dan 
disimpan. Bilangan sel bernukleus yang rendah dan jumlah isipadu darah tali pusat 
rendah merupakan dua penyebab tertinggi pembuangan darah tali pusat. Analisis faktor 
ibu dan bayi menunjukkan tempoh kehamilan berkait secara negatif dengan jumlah 
isipadu darah tali pusat (r= -0.182, p=0.001). Manakala berat lahir bayi berkait secara 
positif yang lemah dengan jumlah isipadu darah tali pusat (r=0.174, p=0.001) dan 
TNC/unit (r=0.116, p=0.034).  Kandungan hematopoetik kesemuanya adalah berkaitan; 
jumlah isipadu darah tali pusat dengan TNC/unit (r=0.594, p<0.001), jumlah isipadu 
darah tali pusat dengan CD34+/unit (r=0.364, p<0.001) dan jumlah isipadu darah tali 
pusat dengan CFU (r=0.177, p< 0.015). 
 
Kesimpulan: Kajian ini mendapati faktor ibu dan bayi berhubungkait dengan 
kandungan hematopoetik darah tali pusat. Faktor yang dikenalpasti ialah tempoh 
kehamilan ibu dan berat lahir bayi mempunyai  hubungkait yang signifikan dengan 
jumlah isipadu darah tali pusat dan bilangan sel bernukleus. 
 
Kata Kunci: Darah tali pusat, pendermaaan, bank darah tali pusat, faktor ibu dan bayi 
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Abstract 
 
Background: Umbilical cord blood (UCB) is an alternative source of allogeneic 
haematopoietic stem cells for transplantation. The quality of collected UCB depends on 
its haematopoietic content which directly influences the engraftment and the therapeutic 
outcome. To ensure the quality of stored UCB, the acceptance criteria were created at 
the UCB bank in National Blood Centre (NBC) based on established international 
standard, which resulted in a high discard rate. This study aims to determine the 
association of maternal and neonatal factors that could influence the quality of 
haematopoietic contents of the UCB collections thus guide the choice of donors and 
reduce wastage. 
 
Methods/Design: This is a retrospective cross-sectional study performed by reviewing 
records of 339 cord blood donations which were successfully cryopreserved in 2014 at 
the NBC, Malaysia. The data on stored UCB analysed were the UCB volume, total 
nucleated cell (TNC) count, CD34+ cells concentration, and colony forming units 
(CFU). The maternal factors analysed were age, race, gravid status, gestational period 
and blood group while the neonatal characteristics included gender, neonatal birth 
weight and blood group. One-way ANOVA, independent t-test, Pearson correlation, and 
single linear regression were used to determine the association between the factors and 
the haematopoietic contents of the UCB collected.  
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Results: Based on the NBC report, 39% (692) of the total UCB collected (1781) in 
2014 met the acceptance criteria and stored. Low TNC and low UCB volume accounted 
for the highest reasons for UCB discard. Analysis of the maternal and neonatal factors 
showed that gestational age has a weak negative correlation with UCB volume           
(r= -0.182, p=0.001). While neonatal birth weight, is significant but showed weak 
correlation with CB volume (r=0.174, p=0.001) and TNC count/unit (r=0.116, 
p=0.034). Haematopoietic contents are all interrelated; the UCB volume with TNC 
count/unit (r=0.594, p<0.001), UCB volume with CD34+/unit (r=0.364, p<0.001) and 
UCB volume with CFU (r=0.177, p< 0.015).  
 
Conclusions: This study concluded that maternal and neonatal factors were associated 
with the UCB haematopoietic contents. The factors identified were gestational age of 
the mother and new born weight which had significant association with the UCB 
volume and TNC count. 
 
Keywords: Umbilical cord blood, donation, cord blood banking, maternal and neonatal 
factors 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Overview 
1.1.1 Introduction 
Haematopoietic stem cell transplantation (HSCT) has become a standard treatment for 
many haematological malignancies (Little and Storb, 2002) and certain non malignant 
conditions (Harris 2008). It involves the infusion of haematopoietic stem cells (HSC) 
with the intention to restore and replace the haematopoietic system (Sureda et al., 2015; 
Hatzimichael and Tuthill, 2010). The sources of HSC are either harvested from the 
patient themselves, known as autologous HSCT, or from matched healthy donors, such 
as in allogeneic HSCT (Henig and Zuckerman, 2014). 
 
However, for many patients requiring allogeneic HSCT, fully compatible human 
leucocyte antigen (HLA) matched donors cannot be found in a timely manner 
(Kurtzberg et al., 2008). In this situation, umbilical cord blood (UCB) serves as a good 
alternative source of HSCs for transplantation (Little and Storb, 2002) as it is still 
possible to be performed despite the HLA mismatch (Gluckman and Rocha, 2009). 
 
The first successful allogeneic UCB transplant in 1988 (Gluckman 2000), has paved 
way to currently more than 30,000 umbilical cord blood transplantation (UCBT) 
performed worldwide (Ballen et al., 2013). There were promising results with paediatric 
cases, yet the initial experiences of UCB with adults were associated with high 
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mortality rate (Ballen et al., 2013). However, advancements have been made in UCBT 
for adult, which include improved patient selection, better supportive care, and 
transplantation with higher infused cell dose have improved the chance of survival 
(Ballen et al., 2013). Results from several studies have revealed the comparable 
outcome of UCBT in adults compared to fully matched bone marrow (BM) transplant. 
This further support the use UCB as an alternative stem cell source for adult patients 
lacking HLA matched BM donor (Gluckman and Rocha, 2009). 
 
1.1.2 Challenges in UCBT 
There are many challenges faced by the UCB banks apart from high cost, donor 
recruitment and funding. Getting quality UCB for storage is one that is difficult to 
overcome. Despite promising results, there is significant delayed engraftment 
implicated in UCBT (Smith and Wagner, 2009). The main factors which influence 
engraftment are the cell dose of total nucleated cells (TNC) (Danby and Rocha, 2014), 
CD34+ cell concentration (Jaime-Perez et al., 2011) and the degree of HLA matching 
(Danby and Rocha, 2014). UCB unit which contains high TNC count may yield more 
stem cells, and subsequently provide greater probability of engraftment (Patterson et al., 
2015).  
 
The cord blood units collected by the UCB bank which meets the minimum cut off 
volume and TNC count set would be processed and stored. The volume of UCB 
correlates well with TNC count and CD34+ cell number (Allan et al., 2013), hence it is 
the first criteria for storage by providing a quick estimation of UCB with bankable 
qualities. 
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 However, one of the problems faced by the public UCB bank is to collect the cord 
blood units with enough cell dose of the TNC (Omori et al., 2008). Various reports 
showed that more than 50% of the UCB collection were discarded and were not 
subjected to further processing due to this problem (Wang et al., 2014; Volpe et al., 
2011). This causes significant amount of wastage, financially as well as manpower.  
 
This problem contributes to the UCB bank’s challenge to maintain financial 
sustainability (Magalon et al., 2015), as there is high cost implication involved (Sirchia 
et al., 1999; Petrini 2014).  Thus, improvement in cord blood banking is needed in order 
to be more cost effective which include improving the collection performance as well as 
optimising the donor selection (Magalon et al., 2015). 
 
 
1.2 Justification and benefits 
National Blood Centre (NBC), store more than 7500 units of UCB, which makes it the 
largest public UCB bank in Malaysia. The UCB collected are primarily for 
transplantation purpose.  Thus, it is of utmost importance to collect and preserve the 
UCB units of the best quality to ensure the desirable outcome in transplant is achieved. 
This is dependent on the number of haematopoietic stem cells available in the UCB 
which is reflected in the number of TNC count, CD34+ cells and colony forming units 
(CFU).The acceptance criteria for bankable cord blood in NBC are UCB volume and 
TNC count, based on international standards. It is also in line with clinicians’ preference 
of using the HSC source with the higher TNC count that directs the UCB collection to 
only preserve those with high likelihood to be used. 
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This has resulted in a high rate of rejection as revealed in the 2014 NBC statistics, more 
than 50% of the total UCB collected did not fulfill the minimum required criteria 
needed for banking. The rejections were primarily due to low TNC count as well as 
UCB volume. Thus, it would be beneficial to explore the selection and collection 
process before the UCB is processed to improve rate of acceptance. 
 
Since the UCB are collected from healthy pregnant mothers, it would be best to identify 
whether the donor factors which include the maternal and neonatal factors would 
influence the quality of the UCB. This has been suggested by a previous study, which is 
to optimise donor selection in order for the UCB bank to be more cost effective 
(Magalon et al., 2015). 
 
Thus, this study aims to analyse the maternal and neonatal factors and its influence on 
the quality of banked UCB collection in NBC. Therefore, the impact of various 
maternal and neonatal factors on the haematopoietic contents of the collected UCB units 
could be evaluated. This information will be utilised to facilitate and optimise the 
selection of the cord blood donor that would produce UCB that meet the required 
criteria of having the bankable and better quality UCB content. From this study, it is 
hoped that there will be improvement in selection of pregnant mothers that can 
potentially provide quality UCB to be collected and processed, thus creating a more 
efficient cord blood banking programme. The improvement in efficiency would also 
contribute toward cost saving. This study would also provide the baseline database of 
the UCB donors that would be of importance for future research as well as the 
expansion of the national cord blood collection program 
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CHAPTER 2 
OBJECTIVES 
2.1 General Objective 
To determine the maternal and neonatal factors associated with haematopoietic contents 
among successfully banked and cryopreserved UCB blood units from January until 
December 2014 in NBC. 
2.2 Specific objectives 
• To determine the proportion of stored UCB units among donors in NBC. 
• To describe the demographic factors among stored UCB donors from 
January until December 2014 in NBC. 
• To determine the association of maternal and neonatal factors with the 
haematopoietic contents of stored UCB units among UCB donors in NBC. 
• To determine the association between: 
o UCB volume unit with TNC count, CD34+cell concentration and 
CFU. 
o TNC count with CD34+ cell concentration and CFU. 
2.3 Hypothesis 
• The maternal and neonatal factors are significantly associated with 
haematopoietic contents of UCB. 
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2.4 Conceptual Framework 
There are a few factors that may influence the haematopoietic contents of UCB as 
shown in the figure below. In this current study, the effect of maternal factors (age, race, 
gravid status, blood group and gestational age) and neonatal factors (newborn weight, 
gender and blood group) on the haematopoietic contents of UCB were examined. The 
association among the haematopoietic contents of UCB is also analysed. 
 
 
 
Figure 2.1: Analysis of the maternal factors and neonatal factors affecting the 
haematopoietic contents of UCB. 
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CHAPTER 3 
 
LITERATURE REVIEW 
 
3.1 Haematological diseases 
Haematological diseases are disorders affecting haematopoietic cells which compromise 
the normal functions of red blood cells, white blood cells or platelets. Stem cell 
transplantation is capable of restoring normal blood homeostasis by replacing diseased 
cells with healthy haematopoietic stem cells.  
 
3.2 Haematopoietic stem cell transplantation 
Haematopoietic stem cells (HSCs) are self-renewing, multipotent cells which are 
isolated from the blood or bone marrow, and capable of giving rise to all haematopoietic 
cell types (Figure 3.1). These HSCs have full lineage differentiation capability to form 
more restricted oligopotent progenitors, the common lymphoid progenitor (CLP) and 
the common myeloid progenitor (CMP) (Seita and Weissman, 2010). The self-renewal 
capacity and differentiation ability is gradually lost as it matures into cells with specific 
function. The CLPs serve as the precursors of all lymphoid cells while CMPs are the 
precursors of all myeloid cells (Reya et al., 2001). Eventually, the CMPs will 
differentiate to granulocyte/macrophage progenitors (GMPs), which become committed 
into the granulocyte-monocyte lineage, while the MEPs, which produce erythroid and 
megakaryocyte cells. Whereas for the CLPs, they can give rise to B and T cell 
precursors and commit to the T and natural killer lineages (Doulatov et al., 2012). These 
unique properties confer HSCs the ability to reconstitute bone marrow and restore 
haematopoiesis following transplantation (Seita and Weissman, 2010). 
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Figure 3.1: Model of the haematopoietic hierarchy (adapted from Seita and 
Weissman, 2010). HSC: Haematopoietic stem cell, CLP: Common lymphoid 
progenitor, CMP: Common myeloid progenitor, MEP: Megakaryocyte/Erythrocyte 
progenitor, GMP: Granulocyte/Macrophage progenitor, MkP: Megakaryocyte 
progenitor, EP: Erythrocyte progenitor, GP: Granulocyte progenitor, MacP: 
Macrophage progenitor, DC: Dendritic cell, NK: Natural killer, Lin: Lineage markers 
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Haematopoietic stem cell transplantation (HSCT) involves the infusion of HSCs with 
the intention to restore and replace the haematopoietic system and usually is preceded 
by a myeloablative preparative regimen (Sureda et al., 2015; Hatzimichael and Tuthill, 
2010). It has now become a standard treatment for many haematological malignancies 
(Little and Storb, 2002). It serves as the only proven modality of treatment and a hope 
of a long-term cure for certain non-malignant conditions (Harris 2008). Over the last 
two decades, the HSCT technology has undergone rapid expansion and constant 
development to extend its use in treating autoimmune and inherited metabolic disorders 
(Duncombe 1997; Henig and Zuckerman 2014). 
 
There are two types of HSCT depending on the source of HSCs.  In autologous HSCT, 
HSCs are harvested from the recipient themselves. For allogeneic HSCT, the source of 
stem cells is from healthy donors (Henig and Zuckerman, 2014). These donors may 
either be related or unrelated to the recipient, but possessing suitable cells for 
transplantation determined by the HLA (Ezzone and Schmit-Pokorny, 2007).  Part of 
the protocol of HSCT involves the administration of high doses of chemotherapy for 
both malignant and non-malignant diseases (Goncalves et al., 2009). After 
myelosuppression is induced, autologous or allogeneic HSCs are used as to restore the 
haematopoiesis (Seita and Weissman, 2010).  
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Table 3.1:Types of transplantation according to diseases (adapted from Henig and Zuckerman, 2014) 
 Autologous 
Transplantation 
Allogeneic Transplantation 
Malignancies Multiple myeloma 
Non-Hodgkin lymphoma 
Hodgkin disease 
Acute myeloid leukaemia 
Neuroblastoma 
Ovarian cancer 
Germ cell tumors 
Ovarian cancer 
Germ cell tumors 
Acute myeloid leukaemia 
Acute lymphoblastic 
leukaemia 
Chronic myeloid leukaemia 
Myelodysplastic syndromes 
Myeloproliferative 
neoplasms 
Non-Hodgkin lymphoma 
 
Non-malignant 
disorder 
Autoimmune disease 
Amyloidosis 
Aplastic anaemia 
Paroxysmal nocturnal 
haemoglobinuria  
Fanconi’s anaemia 
Diamond-Blackfan anaemia 
Thalassaemia major 
Sickle cell anaemia 
Severe combined 
immunodeficiency 
Wiskott–Aldrich syndrome 
Inborn errors of metabolism 
Congenital neutropaenia 
syndromes 
 
 
 
HSCT is indicated based on the patient’s medical condition, treatment purpose, and the 
source of stem cells, be it allogeneic or autologous (Hatzimichael and Tuthill, 2010). 
Multiple myeloma, (50%), lymphomas (41%) and leukaemias (3%) are the most 
common diseases treated with autologous HSCs. As for acute myeloid leukaemia 
(AML) and acute lymphoblastic leukaemia (ALL), more than 50% of the cases involved 
allogeneic HSCT (Table 3.1) (Henig and Zuckerman, 2014). 
 
Autologous HSCT involves the use of the patient’s own marrow to reestablish 
haematopoietic cell function after the administration of high-dose chemotherapy.  The 
major problem is that malignant cells, with their inherent resistance to chemotherapy, 
11 
 
might still survive and their reinfusion probably contributes to the high incidence of 
relapse observed after this form of therapy (Goncalves et al., 2009). 
 
Allogeneic HSCT involves the administration of high doses of chemotherapy for both 
malignant and non-malignant diseases (Goncalves et al., 2009). The conditioning 
regimen aims to eradicate malignant cells, ineffective haematopoietic cells, and host 
immune cells, which may reject the donor cells (Hatzimichael and Tuthill, 2010). One 
advantage of allogeneic stem cells is its graft versus tumour effect that eradicates 
residual disease and prevent relapse (Hatzimichael and Tuthill, 2010). 
 
Allogeneic HSCT has been proven to be an effective treatment for haematological 
malignancies (Nelson and Paulos, 2015) and thalassaemia (Isgro et al., 2010).  
However, the main obstacle for allogeneic HSCT lies in the variation of normal human 
genomes which potentially induce immunogenic reaction causing graft rejection, graft 
versus host disease or graft versus tumour reaction after transplantation (Nowak 2008). 
These rejections are mainly mediated by HLA (Little and Storb, 2002) which is encoded 
by the major histocompatibility complex (MHC). The HLA match between a donor and 
recipient is determined by a genetic analysis performed prior to a transplant. Currently 
the standard of HLA matching is by doing HLA at A, B, C, DRB1 and DQB1 genetic 
loci (Nowak 2008).  
 
The use of HSCT continues to expand and evolve with improving safety and efficacy to 
include wider indications.  It has been proven to be the chosen treatment modality as it 
offers higher chance of cure and longer survival (Maziarz  et al., 2014).  Yet, there is 
still high morbidity associated with HSCT arising from the high dosage of 
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chemotherapy. This confers substantial drug toxicities and complications from 
prolonged immunodeficiency to the patients (Hatzimichael and Tuthill, 2010). 
However, advancement such as specific scoring systems have been developed reduces 
the risk of transplantation related mortality (Henig and Zuckerman, 2014). 
 
3.3 Limitation of HSCT 
The most ideal scenario for allogeneic transplantation is having a fully matched donor 
possessing HLA allele HLA-A, -B, -C, and -DRB1 compatible with the recipient 
(Eapen et al., 2014). However, only one third of these patients were able to receive bone 
marrow HSC from HLA matched related donor (La Nasa et al., 2002; Ballen et al., 
2001). About 50 -70% of the patients in need of HSC transplant are still unable to find a 
suitable related or unrelated adult donor especially within a short time period in the 
United States. Despite 13 million of unrelated adult donor volunteers registered in the 
database of the National Marrow Donor Program (NMDP) and other international 
registries (Kurtzberg 2009), it still remains a challenge to find a suitable matched donor 
due to the time and cost incurred. This problem becomes more difficult in patients 
among ethnic minorities due to the limited donor availability (Kurtzberg 2009). The 
challenge for countries with diverse racial and ethnic backgrounds like in Malaysia is to 
include as many ethnic groups into the bone marrow registry as well as UCB bank. 
 
The recommended alternate HSC sources for such patients include haploidentical 
related donors, matched unrelated donors (MUD), mismatched unrelated donor and 
umbilical cord blood (UCB). (Ballen et al., 2013); (Fabricius and Ramanathan, 2016). 
Haploidentical donors share one similar HLA haplotype with the recipient, and they are 
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commonly the biological parents, children, full or half siblings as well as collaterally-
related donors. This measure allows transplantation to be performed more promptly 
than the traditional transplantation with unrelated donor grafts. Yet, it will impose a risk 
of introducing triggering intense bidirectional alloreactivity and high incidences of graft 
rejection as well as graft-versus-host disease (GVHD) (Fabricius and Ramanathan, 
2016). A study revealed that a single or two HLA mismatches (2 out of 8) could risk 
patients’ survival, of which a single HLA mismatch could introduce 25% increase in the 
risk of mortality in comparison to a fully  matched transplant (Anasetti et al., 2012).  
 
3.4 UCB HSCs in HSCT 
UCB is an ideal source of stem cells for allogeneic HSCT, and the cells commonly 
serve as an alternative source for patients who do not have matched HLA-compatible 
donors (Querol et al., 2010). Cord blood HSCs comprise of progenitor cells that are 
capable to engraft and reconstitute the entire haematopoietic system in recipients 
(Querol et al., 2010). 
 
The cord blood is obtained from consented healthy mothers during their third stage of 
labour, immediately or prior to placental expulsion (Solves et al., 2005). UCB is 
collected either as ex utero or in utero method of collection. During ex utero collection, 
the UCB is collected after the delivery of placenta where the placenta will be placed on 
a sterile surgical tray. For in utero collection, the UCB is collected prior to the delivery 
of the placenta immediately after the umbilical cord is clamped. Both strategies employ 
gravitational method to drain UCB from umbilical vein into a sterile collection bag with 
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anticoagulant (Solves et al., 2003). In NBC, UCB is collected using in utero method 
which has also been found to be a better approach (Solves et al., 2003).  
 
UCB offers several advantages such as the relative ease of procurement procedure, as it 
entails a safe procurement method with minimal of risk to donors (Wang et al., 2014), 
in addition to reduced risk of disease transmission (Gluckman et al., 2011). UCB also 
has a large donor pool, mostly made readily available within short dispatch time (Oran 
and Shpall, 2012). It is estimated that there are more than 500,000 units of UCB 
available for unrelated donor haematopoietic stem cell transplant (Oran and Shpall, 
2012). 
 
Furthermore, UCB are generally immunogenically naïve, and thus better serves as an 
alternative to those patients of diverse ethnic backgrounds, whom do not have a suitably 
matched, unrelated voluntary donor identified in the required time frame (Ballen et al., 
2013).  Compared to bone marrow transplantation (BMT), of which a fully compatible 
HLA match is often required, UCBT can still be performed when the donor cells 
possess HLA disparities (Gluckman 2000; Gluckman and Rocha, 2009). 
 
Primitive CD16-CD56++ natural killer (NK) cells, which possess significant 
proliferative and cytotoxic capacities, are also found in abundance in UCB. These cells 
can be further expanded using IL-12 or IL-15, and potentially promotes graft versus 
leukaemia (GVL) effect (Cohen and Nagler, 2004).  Furthermore, the UCB derived 
HSCs were also found more primitive compared to those present in the bone marrow 
(BM) or peripheral blood (PB) (Hordyjewska et al., 2015). The highly-proliferative 
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colony-forming cells are found in large quantity in UCB which exceeds eight times that 
of bone marrow (Nimgaonkar et al., 1995; Hordyjewska et al., 2015).  This confers 
UCB HSCs with a greater capability to repopulate the recipient’s haematopoietic 
system. 
 
3.5 Progress of UCBT 
The first UCBT was performed in October 1988 to treat a patient with Fanconi 
Anaemia. Twelve years after the procedure, the patient had progressed well and had full 
donor haematopoietic reconstitution (Gluckman 2000). In 1993, 25 successful 
transplantations were performed using unrelated UCB in the New York, demonstrating 
its clinical feasibility (Ballen et al., 2013). Analysis between UCBT and BMT with the 
present HLA matching practice showed that HLA matched and one or two antigen HLA 
mismatched UCB can be transplanted to treat children with acute leukaemia. Better 
HLA matching outcome and higher cell dose were found to significantly decrease the 
risk of transplant related mortality (Eapen et al., 2007).  
 
Eurocord, a collaborative effort of public European cord blood banks and registries 
(http://www.eurocord.org/about-eurocord.php), compared the outcomes of matched 
unrelated BMT to HLA mismatched UCBT.  They observed that UCBT are associated 
with delayed engraftment and lesser event of acute and chronic GVHD, yet relapse rate, 
overall survival, and leukaemia-free survival (LFS) were similar to matched unrelated 
donor (MUD) bone marrow (Ballen et al., 2013).  
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Another study had compared fully HLA matched unrelated adult peripheral blood (PB) 
stem cell transplant to HLA mismatched UCB transplant for patients with 
myelodysplastic syndromes (MDS) from 2005 to 2011(Ruggeri et al., 2013). The 
results revealed that a fully HLA matched unrelated matched PB donor, a 9/10 HLA 
matched PB donor or mismatched UCB gave similar outcomes. Therefore, for MDS 
patients without a fully HLA matched unrelated donor, a graft with 9/10 HLA matched 
or a HLA mismatched UCB are both alternative options for transplantation (Ruggeri et 
al., 2013). 
 
A further study by Eurocord, comparing adults with acute leukaemia receiving either a 
full 6/6 HLA matched unrelated BMT and a mismatched UCB transplant showed 
promising results. UCBT had a similar LFS to BMT despite a delay in engraftment. 
Moreover, Centre for International Blood and Marrow Transplant Research (CIBMTR) 
demonstrated that UCB transplant in adults with malignancies have produced the same 
LFS as compared to one HLA antigen mismatched BMT (Gluckman and Rocha, 2009). 
 
Several comparative studies and meta-analysis concluded that the outcome of UCB 
transplant in adults was comparable to fully matched bone marrow (BM) transplant. 
Thus, UCB is an alternative source of allogeneic stem cell for adult patients lacking 
HLA matched BM donor (Gluckman and Rocha, 2009). 
 
3.6 UCB content and therapeutic  
Haematopoietic engraftment refers to the period post transplantation where the blood 
parameters have recovered and transfusion support is not required anymore (Allan et 
al., 2013). It is one of the parameters in determining the successful clinical outcomes of 
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transplantation (Ratajczak & Suszynska, 2016). There was significant delay of 
haematopoietic engraftment for UCB graft compared with other sources of HSC, 
causing the period of aplasia post transplantation to be to longer as well. This result in 
UCBT has substantial risk of infection-related morbidity and mortality (Danby and 
Rocha, 2014). 
 
The main factors influencing engraftment are the cell dose of TNCs (Danby and Rocha, 
2014), CD34+ cells concentration (Jaime-Perez et al., 2011) and the degree of HLA 
matching (Danby and Rocha, 2014).  The cell dose refers to the TNC count per recipient 
body weight in kilogram, and it is proportionate to the haematopoietic potential of UCB 
collections (Migliaccio et al., 2000). The cell dose in UCB unit is one of the most 
critical determinants of therapeutic efficacy, transplantation related mortality as well as 
overall survival after UCBT (Scaradavou et al., 2013).  
 
TNC refers to the number of nucleated cells that can be found in the circulation for at 
least a period of their life (Walker et al., 1990). A higher TNC count reflects a higher 
proportion of proliferative stem cells, which offer greater probability of engraftment 
(Patterson et al., 2015). UCBT trials in adult have showed that higher UCB derived 
TNC count was associated in earlier neutrophil recovery, while greater event free 
survival was found to be associated with greater CD34+ cell dose (1.2 x 105 cells/kg) 
(Oran and Shpall, 2012). However, the major limitation in UCBT is the infrequent 
availability of UCB units with the minimum acceptable pre-cryopreservation cell dose 
of TNC count of 2.5 X 107/kg patient body weight (Scaradavou et al., 2013).  
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Other informative indices of haematopoietic potential include enumeration of CD34+ 
cell and colony forming progenitor cells or CFU (Migliaccio et al., 2000). CD34 is a 
transmembrane phosphoglycoprotein and it is regarded as a marker of HSC and 
haematopoietic progenitor cells (Sidney et al., 2014). It has been shown that CD34+ cell 
content influence engraftment and survival after unrelated UCBT (Jaime-Perez et al., 
2011). CFU assays are in vitro functional assays to identify haematopoietic progenitors 
(Frisch and Calvi, 2014). Colonies of maturing cells are produced as the 
haematopoietic progenitor cells proliferate and differentiate when cultured using 
methylcellulose-based medium enriched in a suitable environment (Wognum et al., 
2012). This assay is important in evaluation of functional capacity of HSCs after 
thawing the UCB product, however due to the variation of colony setup and counting 
between centres, there is difficulty in establishing a generalized CFU dose for 
transplantation purposes (Hough et al., 2016).   
 
A recommendation for a standard UK approach to incorporate UCB into clinical 
transplantation practice was accomplished after a meeting between senior transplant 
physician, UK cord blood banks and scientists from across UK. Through these 
recommendations, it was aimed to focus on UCB unit selection, donor selection strategy 
and conditioning regimens. According to the consensus, TNC is regarded as the primary 
cell dose criterion. Despite the fact that the CD34+ cell count may be a better marker of 
cell content, there are historical differences in CD34 quantification methodologies and 
availability which makes interbank comparison difficult. Another good marker of HSCs 
proliferative potential is the CFU in the UCB grafts. However, not many studies have 
documented its’ association with engraftment or survival and not all collection centres 
are able to perform this test due to various reasons (Hough et al., 2016).  Based on these 
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recommendations, TNC is considered as the primary criterion pertaining to UCB 
selection for transplantation in which it is also one of the criteria for banking. Thus it is 
important to see the association of TNC with the other marker of cell content such as 
CD34+ and CFU. 
 
There have also been numerous strategies to optimise cell number and improve the rate 
of neutrophil, platelet recovery, and engraftment after UCBT.  These strategies include 
improving cord blood collection and processing, enhanced HLA matching, improving 
homing and ex vivo expansion of UCB. Usage with other grafts includes double UCB 
grafts, co transplantation with third party donor and infusing with accessory cells 
(Danby and Rocha, 2014).  
 
 
Use of double UCB grafts by co infusing two partially HLA-matched cord blood units 
especially in adult patients has been one of the commonly employed strategies. 
According to the European registry (Eurocord), since 2005 the usage of double UCB 
grafts has even surpassed the number of adult patients transplanted with single cord 
blood units (Sideri et al., 2011). The transplant outcome with regards to the disease free 
survival, neutrophil recovery, transplantation related death, relapse, infection, 
immunologic reconstitution and acute GVHD were found to be similar to the use of the 
single UCB graft. Furthermore, double UCB grafts were also compared to other stem 
cell sources, which include matched sibling donor and matched unrelated donor which 
showed similar outcome for leukaemia free survival at 5 years, transplanted related 
mortality and relapse related death. This method has also been adopted by NBC in 
which all the adult patients utilized double UCB grafts (National Stem Cell 
Coordinating Centre, unpublished data). 
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3.7 UCB banking 
The progression in UCBT has attracted huge interest in establishing cord blood banking 
services worldwide (Gluckman 2009). Cord blood banks are either intended for the 
public use or personal purposes. The first public UCB bank was established in 1993 at 
New York, United States. It has since grown to more than 50 UCB banks worldwide, 
with over 600,000 UCB units stored for transplantation (Ballen et al., 2013; Liu et al., 
2012). With the growth of numerous UCB banks, there was a need to establish good 
practices in regard to umbilical cord blood storage. The Netcord group was founded in 
1998 to accomplish this task. This organization will facilitate donor search, improve the 
quality of grafts, and standardize excellence criteria on an international scale and more 
importantly, to establish procedures for banking accreditation (Gluckman 2009).  
 
Public cord blood banks need to have an optimal inventory in order to have UCB units 
with a good HLA match with a patient, which is dependent on the size of the population 
and presence of ethnic minorities (Querol et al., 2009). Study showed that the likelihood 
of getting UCB with good HLA match would be greater with an inventory of 1 or 2 
units for a population of 1,000 people (Petrini 2014).  
 
Each UCB banking programme establishes its own UCB acceptance criteria prior to 
cryopreservation. Most cord blood centres require a minimum limit of UCB volume and 
TNC count as the main selection factors for cryopreservation (Jaime-Perez et al., 2011; 
Patterson et al., 2015) to facilitate the efficient UCB units for clinical use (Omori et al., 
2012). Yet many countries have reported a high discard rate by adhering to this 
requirement, which contributes to significant amount of wastage in terms of finance and 
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manpower. A higher discard rate would raise the cost in attaining each UCB unit 
(Petrini 2014)  
 
This causes a shortfall in UCB banking as many UCB banks have already found it 
difficult to be sustaining financially (Magalon et al., 2015). There is high cost involved 
in the present standard of UCB banking which include the high personnel cost, 
collection, processing and storage (Omori et al., 2012). An economic study by the 
Spanish Plan Nacional de Sangre de Cordón Umbilical found the minimum cost for 
each UCB unit is €1,300 ($1,760) for collection and processing while €40/year 
($65/year) for storage, based on a 50% discard rate. The cost is increased to €1,600 
($2,170) if the discard rate increases to 65% and reaches almost €1,900 ($2,580) as the 
discard approaches 80% (Petrini 2014) 
 
New strategies and improvising are needed in order to minimize operating costs. 
Among the recommendations include improving collection performance of the UCB 
units as well as optimizing donor selection based on maternal and infant characteristics 
which influence UCB quality (Magalon et al., 2015). 
  
The NBC also faces the same challenge in order to sustain financially with a discard 
rate almost as high as other countries. Currently, it is estimated a minimum cost of RM 
3300 per each UCB stored in NBC rate (unpublished data, Cord blood unit) which 
include the cost of collection, processing and storage for one year, excluding the cost of 
manpower as well as utilities.  
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It would be beneficial to the NBC to implement the proposed recommended strategies 
in order to become more cost efficient. Thus, optimizing the donor selection would 
assist in improvement in UCB collection. By analyzing the donor characteristics with 
the haematopoietic contents of the UCB, this would then help in the selection of donors 
who are most likely to have adequate parameters for banking 
 
3.8 UCBT in Malaysia 
The first public cord blood bank was established by the NBC in 2001, which is located 
in Kuala Lumpur, Malaysia. This was established following the need among paediatric 
patients based on disease population studies. The number of children are diagnosed with 
leukaemia is approximately to be 3000 each year in Malaysia. Currently there are 
26,000 donors for matched unrelated donors under the Malaysian Stem Cell Registry 
whereas it is estimated at least 40,000 donors to have a good match for the purpose of 
allogeneic transplantation (Malaysian Stem Cell Registry, 2013 
http://www.imr.gov.my). 
The expansion of the public cord blood bank’s service by the Ministry of Health was in 
line with the anticipated demand (National standards for cord blood banking and 
transplantation, 2008). Four hospitals were designated as the site of umbilical cord 
blood collection in Klang Valley. General Hospital Kuala Lumpur has started the cord 
blood collection since 2001, followed by Hospital Selayang (2011), Hospital Serdang 
(2012) and Hospital Ampang (2013). These UCB collections are processed and 
subsequently stored in NBC. In April 2010, Hospital Sultanah Bahiyah in Kedah was 
established to cater for the northern population. 
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From its establishment until 2014, over 16,677 units of cord blood units have been 
collected for cord blood transplant but to meet the NCB criteria, only 7,505 UCB units 
were subsequently processed and stored. In this study which analyzed the UCB 
collection in 2014, it was found that from 1781 UCB collected, 58.3% (1045) were 
discarded (unpublished data, Cord blood unit). 
The acceptance criteria for banking in NBC are UCB volume >50mls and TNC count 
more than 6X108 cells. Those UCB which meet the minimum requirement will then be 
processed for enumeration of CD34+ cells and CFU colonies. The NCB standards were 
primarily adapted from the NETCORD-FACT international standards (National 
Standards for Cord Blood Banking and Transplantation, 2008). 
 
Table 3.2: Requirements prior to processing 
Processing requirement: 
UCB volume >50mls 
TNC count >6x108 
Complete documentation 
Temperature storage 22-24 
Processed within 48hours after collection 
 
 
 
However, the donor criteria for donations among pregnant mothers are very general 
(Table 3.3). Currently, the present guideline only focuses on issue of safety of the 
donation and does not help with the selection of likelihood of having bankable UCB 
units.  Thus, by analysing the donor characteristics to see if there are any associations or 
influence towards the quality of the UCB perhaps would enable the UCB collectors to 
predict the donors with higher chance of having better quality UCB units. 
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Table 3.3: UCB donor criteria in NBC (Refer Appendix 1) 
Donor criteria: 
Age >18 years old 
Malaysian 
Married 
Singleton pregnancy 
Gestational age >36 weeks 
Antenatal screening: negative for HIV, 
Hepatitis B, C and Syphilis 
No high risk behaviour 
No chronic illness or regular medication 
No maternal or paternal history of genetic 
disease 
 
 
Cord blood banking is costly to which involve many processes, including collection, 
processing and storage of the store UCB unit. Currently, it is estimated a minimum cost 
of RM 3300 per each UCB, which include the cost of collection, processing and storage 
1 year, excluding cost of manpower as well stored in NBC with the current discard rate 
(unpublished data, Cord blood unit). 
 
Any request for allogeneic stem cell made to the National Stem Cell Coordinating 
Centre (NSCCC) a search will be made to the National Bone Marrow Registry as well 
as to the cord blood unit at NBC. The total request for UCB searches have reached more 
than 355 from all over the country, but there have only been 5 cases of UCBT 
performed using UCB units from NBC (NSCCC census, NBC). These cases involved a 
paediatric patient with aplastic anaemia (2009); adult case of AML (2010); adult case of 
relapse ALL (2013); paediatric patient with Fanconi’s anaemia (2013) and most 
recently an adult patient with ALL (2016) (unpublished data, Cord blood unit).  
